3 results about "Amyloid deposition" patented technology

The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (Aβ, Abeta) peptide, a tau peptide, and an alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of Aβ and tau and an alpha-synuclein, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds and an alpha-synuclein synucleinopathies in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and amyloid-beta and an alpha-synuclein accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide and an alpha-synuclein peptide.

The present application relates to the technical field of Congo red derivative photocatalytic probe application, and particularly relates to a Congo red derivative photocatalytic probe, a preparation method and a use method thereof, comprising a compound I, the compound I is selected from at least one of the Congo red derivative photocatalytic probes, and the Congo red derivative photocatalytic probe comprises two arene, the arene represents an aromatic heterocycle, and the aromatic heterocycle is selected from one of a benzene ring, furan, thiophene and a naphthalene ring. The Congo red derivative photocatalytic probe provided by the present application can specifically label amyloid plaques in AD brain tissue slices, the binding affinity is significantly improved (Kd of Aβ 1‑40 The Congo red derivative photocatalytic probe can reveal the molecular heterogeneity of amyloid deposition and the key regulatory role of the mitochondrial autophagy-lysosome axis, provide a new tool for AD pathological mechanism research, support proteomic analysis and pathological mechanism analysis across brain regions (hippocampus / cortex), and protect the molecular structure and application in the research of neurodegenerative diseases.

The present application relates to the technical field of medicine, and more particularly to a polypeptide for inhibiting and / or eliminating beta-amyloid aggregation and application thereof. The present application first develops a functional active polypeptide ANI-1 which can act on diseases caused by beta-amyloid aggregation and deposition such as Alzheimer's disease from multiple targets, so as to effectively prevent and treat the diseases. The polypeptide ANI-1 of the present application has the functions of eliminating A beta aggregation, delaying behavioral decline caused by beta-amyloid toxicity (anti-paralysis, promoting movement), inhibiting neurogenic inflammation related to beta-amyloid deposition and enhancing antioxidant defense, has better overall efficacy and neuroprotective potential, and can provide a new idea for developing a multi-target drug for diseases caused by beta-amyloid aggregation and deposition such as Alzheimer's disease.